Beaconlight Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Beaconlight Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-11,183	Closed	-$3.42M	–	28
2019 Q1	$3.42M	Buy	+11,183	New	+$3.02M	0.97%	22
2018 Q2	–	Sell	-37,490	Closed	-$9.38M	–	22
2018 Q1	$9.38M	Sell	37,490 -15,515	-29%	-$3.95M	3.52%	12
2017 Q4	$12.7M	Sell	53,005 -14,869	-22%	-$3.6M	4.64%	7
2017 Q3	$15.1M	Buy	67,874 +21,879	+48%	+$4.92M	7.96%	4
2017 Q2	$10.4M	Buy	45,995 +4,100	+10%	+$893K	8.37%	4
2017 Q1	$8.35M	Buy	41,895 +13,900	+50%	+$2.68M	5.31%	6
2016 Q4	$5.1M	Buy	27,995 +10,400	+59%	+$1.77M	2.75%	16
2016 Q3	$2.88M	Buy	+17,595	New	+$2.67M	1.04%	25

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Beaconlight Capital's BIO Position: Q2 2019 in Review

Beaconlight Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2019, closing a stake of 11,183 shares — an estimated $3.42M sold.

Beaconlight Capital first reported a position in BIO in Q3 2016 and held it in 8 quarters. The position peaked at $15.1M in Q3 2017. 330 funds tracked by Wall St. Rank hold BIO as of Q2 2019.

Beaconlight Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2019 after selling out during the quarter.
Beaconlight Capital sold 11,183 Bio-Rad Laboratories Class A shares in Q2 2019, an estimated $3.42M.
Beaconlight Capital first reported a position in Bio-Rad Laboratories Class A in Q3 2016 and held it in 8 quarters.
Beaconlight Capital's Bio-Rad Laboratories Class A position peaked at $15.1M in Q3 2017.
330 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2019.

Based on Beaconlight Capital's 13F filing for Q2 2019, filed 14 Aug 2019.